National Guideline Clearinghouse | Screening for cervical cancer.

full-text:
National Guideline Clearinghouse | Screening for cervical cancer.

January 14, 2013

---

New This Week

 

Guideline Title

Screening for cervical cancer.

 

Bibliographic Source(s)

American College of Obstetricians and Gynecologists (ACOG). Screening for cervical cancer. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2012 Nov. 17 p. (ACOG practice bulletin; no. 131). [111 references] PubMed

 

Guideline Status

This is the current release of the guideline.
This guideline updates a previous version: American College of Obstetricians and Gynecologists (ACOG). Cervical cytology screening. Washington (DC): American College of Obstetricians and Gynecologists (ACOG); 2009 Dec. 12 p. (ACOG practice bulletin; no. 109). [96 references]

Obstet Gynecol. 2012 Nov;120(5):1222-38. doi: http://10.1097/AOG.0b013e318277c92a.

ACOG Practice Bulletin Number 131: Screening for cervical cancer.

Committee on Practice Bulletins--Gynecology.

Abstract

The incidence of cervical cancer in the United States has decreased more than 50% in the past 30 years because of widespread screening with cervical cytology. In 1975, the rate was 14.8 per 100,000 women. By 2008, it had been reduced to 6.6 per 100,000 women. Mortality from the disease has undergone a similar decrease from 5.55 per 100,000 women in 1975 to 2.38 per 100,000 women in 2008 (1). The American Cancer Society (ACS) estimates that there will be 12,170 new cases of cervical cancer in the United States in 2012, with 4,220 deaths from the disease (2). Cervical cancer is much more common worldwide, particularly in countries without screening programs, with an estimated 530,000 new cases of the disease and 275,000 resultant deaths each year (3, 4). When cervical cancer screening programs have been introduced into communities, marked reductions in cervical cancer incidence have followed (5, 6). New technologies for cervical cancer screening continue to evolve as do recommendations for managing the results. In addition, there are different risk-benefit considerations for women at different ages, as reflected in age-specific screening recommendations. The ACS, the American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Society for Clinical Pathology (ASCP) have recently updated their joint guidelines for cervical cancer screening (7), and an update to the U.S. Preventive Services Task Force recommendations also has been issued (8). The purpose of this document is to provide a review of the best available evidence regarding screening for cervical cancer.

PMID:

23090560

[PubMed - in process]